Wells Fargo & Company MN trimmed its stake in shares of Sanofi (NYSE:SNY) by 22.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,473,739 shares of the company’s stock after selling 1,018,980 shares during the quarter. Wells Fargo & Company MN owned about 0.14% of Sanofi worth $166,426,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Pennsylvania Trust Co lifted its holdings in shares of Sanofi by 0.4% during the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after buying an additional 37 shares in the last quarter. Rehmann Capital Advisory Group lifted its holdings in shares of Sanofi by 0.7% during the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after buying an additional 47 shares in the last quarter. Weik Investment Services Inc. lifted its holdings in shares of Sanofi by 0.9% during the first quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock worth $267,000 after buying an additional 50 shares in the last quarter. Financial Advisors Network Inc. lifted its holdings in shares of Sanofi by 1.0% during the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock worth $409,000 after buying an additional 84 shares in the last quarter. Finally, First City Capital Management Inc. lifted its holdings in shares of Sanofi by 0.3% during the first quarter. First City Capital Management Inc. now owns 38,289 shares of the company’s stock worth $1,733,000 after buying an additional 100 shares in the last quarter. 9.33% of the stock is owned by institutional investors.
In related news, major shareholder Sanofi acquired 60,595 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were acquired at an average cost of $478.98 per share, for a total transaction of $29,023,793.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.00% of the company’s stock.
Sanofi (NYSE SNY) traded down 0.60% during mid-day trading on Friday, hitting $48.43. The stock had a trading volume of 2,378,561 shares. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24. The firm has a market cap of $121.63 billion, a PE ratio of 11.54 and a beta of 0.88. The company’s 50 day moving average price is $48.30 and its 200 day moving average price is $47.32.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. Analysts anticipate that Sanofi will post $3.34 earnings per share for the current year.
A number of research firms have recently weighed in on SNY. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a report on Friday. Argus reaffirmed a “buy” rating and issued a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Cowen and Company reaffirmed a “market perform” rating and issued a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $54.00.
TRADEMARK VIOLATION WARNING: This article was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.truebluetribune.com/2017/09/17/sanofi-sny-shares-sold-by-wells-fargo-company-mn.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.